Towards human cardiac new approach methodologies (NAMs) to evaluate the combination of repolarization prolonging and shortening drugs: a pilot study
We conclude that cobicistat can attenuate moxifloxacin induced FPDcF prolongation at clinically relevant concentrations <i>in vitro</i>. Taken together, this work provides a foundation to evaluate drug combinations <i>in vitro</i> to aid regulatory decision-making and reduce the dependence on animal studies.
Authors
- Tromondae K. Feaster (ORCID: https://orcid.org/0000-0003-2102-8742)
- Robert Geiger
- Ksenia Blinova (ORCID: https://orcid.org/0000-0003-1123-3152)
- Bhavya Bhardwaj
- Carlos J. Serna
Institutions
- United States Food and Drug Administration (US)
- Center for Drug Evaluation and Research (US)
Publication Details
- Journal
- Frontiers in Drug Discovery
- Published
- 2025-11-10
- DOI
- https://doi.org/10.3389/fddsv.2025.1679626
- Citations
- 1
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- U.S. Food and Drug Administration